Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 11/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 10/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 10/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.38 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2081828 | 0.89 | CHRNA3 (0.61) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL2080560 | 0.86 | CHRNB2 (0.55) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL2081583 | 0.80 | CHRNB2 (0.53) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| SCHEMBL2081201 | 0.74 | CHRNB2 (0.65) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| SCHEMBL2080911 | 0.74 | CHRNB4 (0.59) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| Hydrochloric Acid SCHEMBL2081276 | 0.73 | CHRNB4 (0.58) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| SCHEMBL2082397 | 0.72 | CHRNB2 (0.46) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| SCHEMBL2083087 | 0.70 | CHRNB2 (0.52) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| SCHEMBL2083084 | 0.70 | CHRNB2 (0.52) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 | |
| SCHEMBL2080879 | 0.69 | CHRNB2 (0.54) | CHRNA7CHRNB2CHRNA3CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897611-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1678172-B1 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | TARGACEPT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7402592-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1678172-A2 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Targacept, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037832-A9 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | — | 2006-01-26 | — | — | WO | disclosed |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005037832-A2 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | OPRL1, OPRK1, COMT | CHRNA7 53/4885CHRNB2 25/4885CHRNA3 44/4885 |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CHRNA7 53/4885CHRNB2 25/4885CHRNA3 44/4885 |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CHRNA7 53/4885CHRNB2 25/4885CHRNA3 44/4885 |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CHRNA7 53/4885CHRNB2 25/4885CHRNA3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.